E. Salsitz

发表

Clinical case discussion: treating opioid dependence with buprenorphine.

D. Alford, J. Renner, Judith A Martin, 2007, Journal of addiction medicine.

Safe Methadone Induction and Stabilization: Report of an Expert Panel

P. Levounis, Judith A Martin, L. McNicholas, 2013, Journal of addiction medicine.

Pharmacotherapy of Opioid Addiction: “Putting a Real Face on a False Demon”

T. Wiegand, E. Salsitz, 2015, Journal of Medical Toxicology.

Chronic Pain, Chronic Opioid Addiction: a Complex Nexus

E. Salsitz, 2015, Journal of Medical Toxicology.

Transitioning Stable Methadone Maintenance Patients to Buprenorphine Maintenance

S. Tross, E. Salsitz, C. C. Holden, 2010, Journal of addiction medicine.

Methadone Medical Maintenance: An Early 21st-Century Perspective

M. Kreek, H. Joseph, E. Salsitz, 2015, Journal of addictive diseases.

Methadone maintenance patients in general medical practice. A preliminary report.

D. D. Des Jarlais, E. Pascarelli, H. Joseph, 1988, JAMA.

Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice--a summary report (1983-1998).

H. Joseph, N. Salomon, B. Richman, 2000, The Mount Sinai journal of medicine, New York.

Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction

P. Levounis, D. Alford, S. Wyatt, 2011, Journal of addiction medicine.

Pulmonary actinomycosis in a patient with HIV infection.

E. Salsitz, W. Talavera, C. Widrow, 1989, The Mount Sinai journal of medicine, New York.

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.

Y. Hurd, G. Winkel, E. Salsitz, 2019, The American journal of psychiatry.

Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.

Y. Hurd, An-Li Wang, E. Salsitz, 2021, Cannabis and cannabinoid research.

Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients.

L. Poretsky, H. Joseph, T. Croxson, 1990, Archives of internal medicine.

Pharmacotherapy of Opioid Addiction: “Putting a Real Face on a False Demon”

T. Wiegand, E. Salsitz, 2016, Journal of Medical Toxicology.

Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians’ offices (medical maintenance)

H. Joseph, B. Richman, E. Salsitz, 1994, Journal of General Internal Medicine.

Language Matters: It Is Time We Change How We Talk About Addiction and its Treatment.

P. Cowan, D. Rabago, Michael M. Miller, 2020, Journal of addiction medicine.

The duration dilemma in opioid agonist therapy.

E. Salsitz, A. Dhanda, 2021, Journal of opioid management.

Outcomes of Buprenorphine Maintenance in Office-Based Practice

L. Marsch, A. Rosenblum, S. Magura, 2007, Journal of addictive diseases.

Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder

M. Saheed, M. Lyons, L. Richardson, 2023, JAMA network open.

Chronic Pain, Chronic Opioid Addiction: a Complex Nexus

E. Salsitz, 2016, Journal of Medical Toxicology.

Medical maintenance: A new model for continuing treatment of socially rehabilitated methadone maintenance patients.: (470092004-001)

H. Joseph, B. Richman, E. Salsitz, 1988 .

Commentary on letter entitled, "buprenorphine comes of age".

D. Alford, J. Renner, Judith A Martin, 2008, Journal of addiction medicine.

Opioid Agonist Therapy: The Duration Dilemma

B. Israel, E. Salsitz, 2015 .